Tag: monoclonal antibody
-
Monoclonal Antibody Protects Children from RSV: Real-World Evidence
Groundbreaking real-world evidence supports nirsevimab’s role against RSV In a significant step forward for pediatric infectious disease prevention, a large real-world study published in the Journal of Infection provides fresh evidence that the long-acting monoclonal antibody nirsevimab (Beyfortus) offers protection against respiratory syncytial virus (RSV) infection in children. The findings, drawn from diverse clinical settings,…
-
Monoclonal Antibody nirsevimab Beyfortus Shields Children from RSV
New Evidence Supports nirsevimab Beyfortus in RSV Prevention A comprehensive real-world study published in the Journal of Infection highlights the protective role of the long-acting monoclonal antibody nirsevimab, marketed as Beyfortus, against respiratory syncytial virus (RSV) in children. The findings add to the growing body of evidence that this preventive treatment can reduce RSV infections…
-
Monoclonal Antibody Protects Children from RSV: Real-World Insights
RSV’s Burden on Young Lungs Respiratory syncytial virus (RSV) remains a leading cause of hospitalization for infants and young children worldwide. While most kids recover with supportive care, a subset experiences severe disease that can require intensive care. In this context, scientists have been pursuing preventive strategies beyond vaccines, including long-acting monoclonal antibodies that offer…